CLONIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Clonidine Hydrochloride patents expire, and what generic alternatives are available?
Clonidine Hydrochloride is a drug marketed by Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Anchen Pharms, Bluepharma Industria, Dr Reddys Labs Sa, Jubilant Generics, Lupin Ltd, Novast Labs, Xiamen Lp Pharm Co, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Unichem, Url Labs, Warner Chilcott, Watson Labs, and Yung Shin Pharm. and is included in fifty-seven NDAs.
The generic ingredient in CLONIDINE HYDROCHLORIDE is chlorthalidone; clonidine hydrochloride. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; clonidine hydrochloride profile page.
Summary for CLONIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 32 |
NDAs: | 57 |
Finished Product Suppliers / Packagers: | 39 |
Raw Ingredient (Bulk) Api Vendors: | 136 |
Clinical Trials: | 372 |
Patent Applications: | 1,898 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in CLONIDINE HYDROCHLORIDE? | CLONIDINE HYDROCHLORIDE excipients list |
DailyMed Link: | CLONIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CLONIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute, Egypt | N/A |
Sollis Therapeutics, Inc. | Phase 3 |
Loyola University | Phase 4 |
Pharmacology for CLONIDINE HYDROCHLORIDE
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for CLONIDINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for CLONIDINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
KAPVAY | Extended-release Tablets | clonidine hydrochloride | 0.1 mg and 0.2 mg | 022331 | 1 | 2011-03-04 |
US Patents and Regulatory Information for CLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Warner Chilcott | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 072138-001 | Jun 13, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Chartwell Molecules | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 071785-001 | Apr 5, 1988 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Alembic Pharms Ltd | CLONIDINE HYDROCHLORIDE | clonidine hydrochloride | TABLET;ORAL | 091368-003 | Dec 6, 2011 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |